%0 Journal Article
%T PD-1/PD-L1抑制剂治疗错配修复蛋白缺失/微卫星高度不稳定型结直肠癌的研究现状与进展<br>Research Status and Progress of PD-1/PD-L1 Inhibitors in the Treatment of Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer
%A 王一橙
%A 李洋
%J Advances in Clinical Medicine
%P 978-985
%@ 2161-8720
%D 2023
%I Hans Publishing
%R 10.12677/ACM.2023.131139
%X 结直肠癌(colorectal cancer, CRC)是常见恶性肿瘤之一，近年来以程序性死亡受体1 (programmed cell death-1, PD-1)/程序性死亡受体配体1 (programmed cell death ligand-1, PD-L1)抑制剂为代表的免疫治疗药物应用于结直肠癌的治疗中，但对该种治疗有积极反应的患者为DNA错配修复蛋白缺失(dMMR)微卫星高度不稳定(MSI-H)患者，相关临床试验已在该类患者中取得了一定成功，但仍有部分患者出现耐药情况，导致疾病进展。本文将对PD-1/PD-L1抑制剂治疗dMMR/MSI-H结直肠癌及耐药研究现状及进展进行综述。<br />
Colorectal cancer (CRC) is one of the common malignant tumors. In recent years, immunotherapeu-tic drugs represented by programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors have been applied to the treatment of colorectal cancer. However, the patients who have a positive response to this therapy mainly are those with mismatch repair deficient (dMMR) and microsatellite instability-high (MSI-H). Related clinical trials have achieved certain success in such patients, but drug resistance occurs in some patients and leads to disease progress. This article re-views the current status and progress of PD-1/PD-L1 inhibitors in the treatment of dMMR/MSI-H colorectal cancer and drug resistance.
%K 结直肠癌，错配修复蛋白缺失/微卫星高度不稳定，PD-1/PD-L1抑制剂，耐药<br>Colorectal Cancer
%K Mismatch Repair Deficient/Microsatellite Instability-High
%K PD-1/PD-L1 Inhibitors
%K Drug Resistance
%U http://www.hanspub.org/journal/PaperInformation.aspx?PaperID=60903